Why the study?
Does ticagrelor reduce the composite of death, stroke, recurrent MI, and stent thrombosis compared to high-dose clopidogrel in ACS patients undergoing PCI who are CYP2C19 intermediate or poor metabolizers?
Does ticagrelor reduce the composite of death, stroke, recurrent MI, and stent thrombosis compared to high-dose clopidogrel in ACS patients undergoing PCI who are CYP2C19 intermediate or poor metabolizers?
Ticagrelor significantly reduces ischemic events compared to clopidogrel in ACS patients undergoing PCI who are identified as CYP2C19 intermediate or poor metabolizers.
May support high-dose clopidogrel in IM/PM ACS patients post-PCI; leaves open optimal DAPT strategy pending larger trials.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2016) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: